Intranasal Epitope-Polymer Vaccine Lodges Resident Memory T Cells Protecting Against Influenza Virus.

ABSTRACT: Intranasal vaccines, unlike injectable vaccines, boost immunity along the respiratory tract; this can significantly limit respiratory virus replication and shedding. There remains a need to develop mucosal adjuvants and vaccine delivery systems that are both safe and effective following intranasal administration. Here, biopolymer particles (BP) densely coated with repeats of MHC class I restricted immunodominant epitopes derived from influenza A virus namely NP₃₆₆, a nucleoprotein-derived epitope and PA₂₂₄, a polymerase acidic subunit derived epitope, are bioengineered. These BP-NP₃₆₆/PA₂₂₄ can be manufactured at a high yield and are obtained at ≈93% purity, exhibiting ambient-temperature stability. Immunological characterization includes compari

SUBMITTER: Liu Z 

PROVIDER: S-EPMC11469178 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature